'Overall, I think sector drivers are really flashing green lights': Chico on the biotech sector

Key Concepts

• XBI (SPDR S&P Biotech ETF): A benchmark index for the biotechnology sector.
• Orphan Disease: Rare diseases that affect a small percentage of the population, often incentivizing specific drug development.
• Hereditary Angioedema (HAE): A rare genetic disorder characterized by recurrent episodes of severe swelling.
• PDUFA Date: The Prescription Drug User Fee Act date; the deadline for the FDA to reach a decision on a new drug application.
• Breakthrough Therapy Designation: An FDA process designed to expedite the development and review of drugs intended to treat serious conditions.
• Capsid Technology: The protein shell of a virus used as a vector (delivery vehicle) to transport gene therapy into human cells.
• Duchenne Muscular Dystrophy (DMD): A severe, progressive muscle-wasting disease primarily affecting young boys.

---

Sector Overview: The Biotech Landscape

Laura Chico, Managing Director at Wedbush, notes that the biotech sector is currently experiencing a resurgence. Despite being out of favor with generalist investors for several years, the XBI is currently outperforming the S&P 500.

• Market Drivers: The sector is benefiting from attractive valuations, a return of M&A (Mergers and Acquisitions) activity, and a shift toward "de-risking" strategies in clinical development, which provides investors with greater confidence regarding upcoming catalysts.

---

Investment Picks and Analysis

1. BioCryst Pharmaceuticals (BCRX)

• Target Price: $21
• Focus: Orphan disease (HAE).
• Current Status: Their product, Orladeyo, is on a $600M+ revenue run rate.
• Investment Thesis: The stock trades at a discount (3x revenue) compared to mid-cap peers (6x revenue) due to investor fears regarding competition. Chico argues this is misplaced, as the acquisition of Astria Therapeutics brings Navena Bart into the pipeline.
• Key Catalysts:
  • Navena Bart (HAE preventive): Phase 3 data expected in early 2027. This drug requires only 2–4 administrations per year, potentially disrupting the market.
  • Netherton syndrome program: Readout expected in late 2026. Chico notes that the market currently assigns "zero value" to this program.

2. Viridian Therapeutics (VRDN)

• Target Price: $32
• Focus: Thyroid eye disease.
• Current Status: Pre-commercial, but "launch-ready" with a PDUFA date of June 30th.
• Investment Thesis: Viridian’s drug, Velaglucerase, is a "better mouse trap" compared to the incumbent Tepezza. While both are IV-administered, Viridian’s version requires fewer and shorter infusions.
• Market Disconnect: Consensus revenue estimates for Viridian ($300M over the first eight quarters) are significantly lower than the historical precedent set by Tepezza ($800M in its first four quarters).

3. Solid Biosciences (SLDB)

• Target Price: $16
• Focus: Next-gen gene therapy for Duchenne muscular dystrophy (DMD).
• Investment Thesis: Solid utilizes a proprietary capsid technology designed to target muscle tissue while de-emphasizing the liver, which improves safety and efficacy.
• Regulatory Strategy: The company is employing a "belt and suspenders" approach, proactively soliciting FDA feedback to refine endpoints for potential accelerated approval.
• Outlook: With a Phase 3 study underway and a second program advancing in the clinic, the next 12 months are expected to provide clarity on regulatory requirements and clinical validation.

---

Synthesis and Conclusion

The biotechnology sector is currently characterized by a "positive setup" driven by clinical innovation and strategic de-risking. Laura Chico’s picks highlight three distinct stages of development:

1. BioCryst: A commercial-stage company undervalued due to perceived competitive threats.
2. Viridian: A near-commercial story with a superior product profile ready to challenge an established market leader.
3. Solid Biosciences: A long-term, clinical-stage play focused on next-generation gene therapy technology.

The common thread across these picks is the presence of clear, upcoming clinical or regulatory catalysts that provide a roadmap for potential value realization.